Evogene Ltd. has announced that it will focus its internal AI-driven drug discovery program on Acute Graft-Versus-Host Disease (aGVHD). This decision, made public on October 28, 2026, marks a significant step for the company as it seeks to develop a novel therapeutic solution for a condition that currently has limited treatment options.

Acute Graft-Versus-Host Disease is a serious complication that can arise after hematopoietic stem cell transplantation, affecting a substantial percentage of transplant recipients. The company aims to address the needs of patients who do not respond to steroid treatments, a situation that can lead to severe health risks and high mortality rates.

Background

Evogene Ltd. operates in the agricultural chemicals sector, as classified under SIC 2870. The company is listed on the Nasdaq under the ticker EVGN. Founded with a focus on computational chemistry, Evogene specializes in AI-driven generative design for both pharmaceuticals and agricultural products. Recent filings include a 6-K on October 28, 2026, and multiple Form 3 and 4 filings earlier in the month.

What the Filing Says

The recent filing indicates that Evogene has begun generating a series of novel small-molecule candidates that show high potency and favorable profiles for drug development. The report states, "The program aims to develop a novel, potential first-in-class small-molecule therapeutic targeting a key biological pathway implicated in severe inflammation in patients who do not respond to steroid treatment following hematopoietic stem cell transplantation." This initiative is guided by leading experts in the field, including Dr. Corey Cutler and Prof. Dr. Robert Zeiser.

Impact

This new focus on aGVHD may significantly affect patients suffering from this condition, particularly those who are steroid-refractory. The potential development of a new therapeutic could improve outcomes for these patients and address a substantial unmet medical need, estimated to represent a multi-billion-dollar market opportunity.

What's Next

The filing does not specify what happens next, but the company is expected to advance its lead series toward IND-enabling studies, further developing its AI-driven drug discovery capabilities.